{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T08:24:33Z","timestamp":1775895873558,"version":"3.50.1"},"reference-count":43,"publisher":"Informa UK Limited","issue":"25","license":[{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Kite Pharmaceuticals"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.2217\/fon-2022-0421","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T09:12:07Z","timestamp":1657876327000},"page":"2791-2804","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Patient preferences for treatment in relapsed\/refractory diffuse large B-cell lymphoma: a discrete choice experiment"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3538-0712","authenticated-orcid":false,"given":"Kelly","family":"Birch","sequence":"first","affiliation":[{"name":"PRECISIONheor,\r6550 Rock Spring Dr #155,\rBethesda,\rMD 20817,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia T","family":"Snider","sequence":"additional","affiliation":[{"name":"Kite Pharmaceuticals,\r2400 Broadway,\rSanta Monica,\rCA 90404,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2584-3736","authenticated-orcid":false,"given":"Kevin","family":"Chiu","sequence":"additional","affiliation":[{"name":"OnPoint Analytics,\r200 Powell St #860,\rEmeryville,\rCA 94608,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Baumgardner","sequence":"additional","affiliation":[{"name":"PRECISIONheor,\r6550 Rock Spring Dr #155,\rBethesda,\rMD 20817,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally W","family":"Wade","sequence":"additional","affiliation":[{"name":"Kite Pharmaceuticals,\r2400 Broadway,\rSanta Monica,\rCA 90404,\rUSA"},{"name":"Wade Outcomes Research & Consulting,\r136 U Street,\rSalt Lake City,\rUT 84103,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunjan","family":"Shah","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center,\r1275 York Avenue,\rNew York,\rNY 10065,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,7,15]]},"reference":[{"key":"e_1_3_4_3_1","unstructured":"American Cancer Society\n. Diffuse large B-cell lymphoma. www.cancer.org\/cancer\/non-hodgkin-lymphoma\/about\/b-cell-lymphoma.html"},{"key":"e_1_3_4_4_1","unstructured":"National Cancer Institute: Surveillance Epidemiology and End Results Program\n. Diffuse large B-cell lymphoma (DLBCL). https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2613"},{"key":"e_1_3_4_6_1","unstructured":"National Comprehensive Cancer Network\n. NCCN Guidelines for Patients: diffuse large B-cell lymphoma (2020). www.nccn.org\/patients\/guidelines\/content\/PDF\/nhl-diffuse-patient.pdf"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv304"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100640"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21113906"},{"key":"e_1_3_4_11_1","unstructured":"Sternberg A\n. Liso-cel receives FDA approval for the treatment of R\/R large B-cell lymphoma (2021). www.cancernetwork.com\/view\/liso-cel-receives-fda-approval-for-the-treatment-of-r-r-large-b-cell-lymphoma"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_3_4_15_1","volume-title":"American Society of Hematology","author":"Kamdar M","year":"2021","unstructured":"Kamdar M , SolomonS, ArnasonJet al. Lisocabtagene maraleucel, a CD19-directed chimeric antigen receptor T cell therapy, versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma: results from the randomized phase 3 TRANSFORM study. Presented at: American Society of Hematology. Atlanta, GA (11\u201314 December 2021)."},{"key":"e_1_3_4_16_1","volume-title":"American Society of Hematology","author":"Bishop M","year":"2021","unstructured":"Bishop M , DickinsonM, PurtillD, BarbaP, SantoroA, HamadN. Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed aggressive B-cell non-Hodgkin lymphoma: analysis of the phase III Belinda study. Presented at: American Society of Hematology. Atlanta, GA (11\u201314 December 2021)."},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-021-00635-3"},{"key":"e_1_3_4_18_1","volume-title":"Transplantation & Cellular Therapy Meetings","author":"Elnair R","year":"2021","unstructured":"Elnair R , Schmit-PokornyK, JourdanD, AlE. 358: Assessment of time to CAR-T cell therapy and patients\u2019 outcomes in relapsed or refractory diffuse large B-cell lymphoma based on insurance status (public versus private) and distance traveled to treatment center. Presented at: Transplantation & Cellular Therapy Meetings. IL, USA (8\u201312 February 2021)."},{"key":"e_1_3_4_19_1","volume-title":"American Society of Hematology","author":"Seyedin R","year":"2021","unstructured":"Seyedin R , SniderJT, RajagopalanK, WadeS, GergisU. 1424 Chimeric antigen receptor T-cell therapy treatment patterns: a retrospective cohort analysis of relapsed or refractory diffuse large B-cell lymphoma patients in the US. Presented at: American Society of Hematology. Atlanta, GA (1\u201314 December 2021)."},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002056"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01973"},{"key":"e_1_3_4_22_1","unstructured":"US Food and Drug Administration\n. FDA Patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making (2020). www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical"},{"key":"e_1_3_4_23_1","unstructured":"European Medicines Agency\n. Proposed ICH guideline work to advance patient focused drug development (PFDD): ICH Reflection Paper (2021). www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-reflection-paper-proposed-ich-guideline-work-advance-patient-focused-drug-development-pfdd_en.pdf"},{"issue":"4","key":"e_1_3_4_24_1","first-page":"389","article-title":"The evolving role of patient preference studies in health-care decision-making, from clinical drug development to clinical care management","volume":"19","author":"Jackso Y","year":"2019","unstructured":"Jackso Y , JanssenE, FischerRet al. The evolving role of patient preference studies in health-care decision-making, from clinical drug development to clinical care management. Expert Rev. Pharmacoecon. Outcomes Res.19(4), 389\u2013396 (2019).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7436.360"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.004"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.08.2223"},{"issue":"0","key":"e_1_3_4_28_1","first-page":"1","article-title":"Package \u2018AlgDesign\u2019","volume":"1","author":"Wheeler B","year":"2019","unstructured":"Wheeler B , BraunMJ. Package \u2018AlgDesign\u2019. R Proj. Stat. Comput.1(0), 1\u201325 (2019).","journal-title":"R Proj. Stat. Comput."},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826080-00004"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511805271"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.0198"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1529674"},{"issue":"18","key":"e_1_3_4_33_1","article-title":"CAR T-cell therapy indications grow significantly in 2021","volume":"10","author":"Holmes B","year":"2021","unstructured":"Holmes B . CAR T-cell therapy indications grow significantly in 2021. Target. Ther. Oncol.10(18) (2021). www.targetedonc.com\/view\/car-t-cell-therapy-indications-grow-significantly-in-2021","journal-title":"Target. Ther. Oncol."},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147913"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116596"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015789"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01731-4"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.225"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1783443"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0160"},{"key":"e_1_3_4_41_1","unstructured":"Cancer Stat Facts: NHL \u2014 Diffuse Large B-Cell Lymphoma (DLBCL)\n. National Cancer Institute - Surveillance Epidemiology and End Results Program. Accessed10 July 2022. https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html"},{"key":"e_1_3_4_42_1","unstructured":"US Food and Drug Administration\n. Patient preference information \u2013 voluntary submission review in premarket approval applications humanitarian device exemption applications and de novo requests and inclusion in decision summaries and device labeling: guidance for industry Food and Drug Administration staff and other stakeholders. (August 2016). www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-preference-information-voluntary-submission-review-premarket-approval-applications"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-014-4044-2"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-032483"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01395"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-0421","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:46:18Z","timestamp":1719125178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-0421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":43,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.2217\/fon-2022-0421"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-0421","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}